Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 28, 2024

Polatuzumab Vedotin Plus Rituximab and Lenalidomide for Relapsed or Refractory DLBCL

The Lancet Haematology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Lancet Haematol 2024 Jan 05;[EPub Ahead of Print], P Abrisqueta, E González-Barca, C Panizo, JMA Pérez, F Miall, M Bastos-Oreiro, A Triguero, L Banerjee, A McMillan, E Seymour, J Hirata, J de Guzman, S Sharma, HY Jin, L Musick, C Diefenbach

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading